Mizuho Boosts Amgen (NASDAQ:AMGN) Price Target to $208.00

Amgen (NASDAQ:AMGNGet Rating) had its price objective raised by analysts at Mizuho from $202.00 to $208.00 in a research report issued to clients and investors on Tuesday, The Fly reports. Mizuho’s price target suggests a potential downside of 13.06% from the stock’s previous close.

AMGN has been the subject of a number of other research reports. TheStreet cut shares of Amgen from a “b+” rating to a “c+” rating in a research report on Wednesday, April 27th. Piper Sandler upped their price objective on shares of Amgen from $255.00 to $260.00 in a research report on Thursday, April 28th. Jefferies Financial Group upped their price objective on shares of Amgen from $266.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, February 9th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 5th. Finally, Morgan Stanley cut their price objective on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $240.40.

Shares of Amgen stock opened at $239.24 on Tuesday. The firm has a 50-day moving average of $240.86 and a 200-day moving average of $226.69. The stock has a market cap of $127.80 billion, a PE ratio of 23.55, a PEG ratio of 1.65 and a beta of 0.58. Amgen has a 52-week low of $198.64 and a 52-week high of $258.81. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44.

Amgen (NASDAQ:AMGNGet Rating) last announced its earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. The company had revenue of $6.24 billion during the quarter, compared to analysts’ expectations of $6.09 billion. Amgen had a net margin of 21.75% and a return on equity of 165.95%. During the same quarter in the previous year, the business posted $3.70 earnings per share. Equities research analysts predict that Amgen will post 17.49 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of Amgen in the fourth quarter valued at approximately $26,000. Norwood Financial Corp acquired a new position in shares of Amgen in the fourth quarter valued at approximately $28,000. CKW Financial Group acquired a new position in shares of Amgen in the first quarter valued at approximately $31,000. Bromfield Sneider Wealth Advisors acquired a new position in shares of Amgen in the first quarter valued at approximately $35,000. Finally, PYA Waltman Capital LLC acquired a new position in shares of Amgen in the fourth quarter valued at approximately $34,000. 79.01% of the stock is owned by institutional investors.

Amgen Company Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

The Fly logo

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.